Please use this identifier to cite or link to this item: https://doi.org/10.3390/cancers10120481
DC FieldValue
dc.titleDysregulation of Nrf2 in hepatocellular carcinoma: Role in cancer progression and chemoresistance
dc.contributor.authorRaghunath, A.
dc.contributor.authorSundarraj, K.
dc.contributor.authorArfuso, F.
dc.contributor.authorSethi, G.
dc.contributor.authorPerumal, E.
dc.date.accessioned2021-12-06T04:29:29Z
dc.date.available2021-12-06T04:29:29Z
dc.date.issued2018
dc.identifier.citationRaghunath, A., Sundarraj, K., Arfuso, F., Sethi, G., Perumal, E. (2018). Dysregulation of Nrf2 in hepatocellular carcinoma: Role in cancer progression and chemoresistance. Cancers 10 (12) : 481. ScholarBank@NUS Repository. https://doi.org/10.3390/cancers10120481
dc.identifier.issn2072-6694
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/209645
dc.description.abstractThe liver executes versatile functions and is the chief organ for metabolism of toxicants/xenobiotics. Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third foremost cause of cancer death worldwide. Oxidative stress is a key factor related with the development and progression of HCC. Nuclear factor erythroid 2 [NF-E2]-related factor 2 (Nrf2) is a cytosolic transcription factor, which regulates redox homeostasis by activating the expression of an array of antioxidant response element-dependent genes. Nrf2 displays conflicting roles in normal, healthy liver and HCC; in the former, Nrf2 offers beneficial effects, whereas in the latter it causes detrimental effects favouring the proliferation and survival of HCC. Sustained Nrf2 activation has been observed in HCC and facilitates its progression and aggressiveness. This review summarizes the role and mechanism(s) of action of Nrf2 dysregulation in HCC and therapeutic options that can be employed to modulate this transcription factor. © 2018 by the authors. Licensee MDPI, Basel, Switzerland.
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2018
dc.subjectHepatocellular carcinoma
dc.subjectKeap1-Nrf2-ARE pathway
dc.subjectMicroRNAs
dc.subjectNrf2 dysregulation
dc.subjectPhytochemicals
dc.typeReview
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.3390/cancers10120481
dc.description.sourcetitleCancers
dc.description.volume10
dc.description.issue12
dc.description.page481
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_cancers10120481.pdf3.86 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons